sign101

British Guideline on the MAnAGeMent of AsthMA
815. Campbell L, Klocke RA. Implications for the pregnant patient. Am J
Respir Crit Care Med 2001;163(5).
816. Templeton A, Kelman GR. Maternal blood-gases, (PAO2--PaO2),
physiological shunt and vD/vT in normal pregnancy. Br J Anaesth.
1976;48(10):1001-4.
817. van Hook J, Harvey CJ, Anderson GD. Effect of pregnancy on maternal
oxygen saturation values: use of reflectance pulse oximetry during
pregnancy. South Med J 1996;89(12):1188-92.
818. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do
women with pre-eclampsia, and their babies, benefit from magnesium
sulphate? The magpie trial: a randomised placebo-controlled trial.
Lancet 2002;359(9321):1877-90.
819. Gee J, Packer B, Millen J, Robin E. Pulmonary mechanics during
pregnancy. J Clin Invest. 1967;46(6):945-52.
820. Izci B, Riha R, Martin S, Vennelle M, Liston W, Dundas K, et al. The
upper airway in pregnancy and pre-eclampsia. Am J Respir Crit Care
Med. 2003;167(2):137-40.
821. Chambers C. Safety of asthma and allergy medications in pregnancy.
Immunology & Allergy Clinics of North America 2006;26(1):13-28.
822. Tata L, Lewis S, McKeever T, Smith C, Doyle P, Smeeth L, et al. Effect
of maternal asthma, exacerbations and asthma medication use on
congenital malformations in offspring: a UK population-based study.
Thorax 2008;63(11).
823. Schatz M, Dombrowski M, Wise R, Momirova V, Landon M, Mabie W,
et al. The relationship of asthma medication use to perinatal outcomes.
J Allergy Clin Immunol 2004 113(6).
824. Wilton L, Shakir SA. A post-marketing surveillance study of formoterol
(Foradil): its use in general practice in England. Drug Safety
2002;25(3):213-23.
825. Gluck JC, Gluck PA. Asthma controller therapy during pregnancy.
American Journal of Obstetrics & Gynecology 2005;192(2):369-80.
826. Nelson H, Weiss S, Bleecker E, yancey S, Dorinsky P. The salmeterol
multicenter asthma research trial (SMART Study Group): a comparison
of usual pharmacotherapy for asthma or usual pharmacotherapy plus
salmeterol. Chest 2006;129(1):15-26.
827. Perrio M, Wilton L, Shakir S. A modified prescription-event monitoring
study to assess the introduction of Seretide Evohaler in England: an
example of studying risk monitoring in pharmacovigilance. Drug Saf.
2007;30(8):681-95.
828. Silverman M, Sheffer A, Diaz PV, Lindmark B, Radner F, Broddene
M, et al. Outcome of pregnancy in a randomized controlled study of
patients with asthma exposed to budesonide. Annals of Allergy, Asthma,
& Immunology 2005;95(6):566-70.
829. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis finds use of inhaled
corticosteroids during pregnancy safe: a systematic meta-analysis
review. Human & Experimental Toxicology 2006;25(8):447-52.
830. Källén B. Maternal drug use and infant cleft lip/palate with special
reference to corticoids. Cleft Palate Craniofac J 2003;40(6):624-8.
831. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer
EJ. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol
2007;197(6):585 e1-7; discussion 683-4, e1-7.
832. Bakhireva LN, Schatz M, Chambers CD. Effect of maternal asthma
and gestational asthma therapy on fetal growth. Journal of Asthma
2007;44(2):71-6.
833. Twaites BR, Wilton LV, Shakir SA. Safety of zafirlukast: results of a
postmarketing surveillance study on 7976 patients in England. Drug
Safety 2007;30(5):419-29.
834. Wensley D, Silverman M. Peak flow monitoring for guided selfmanagement
in childhood asthma: a randomized controlled trial. Am
J Respir Crit Care Med 2004;170(6):606-12.
835. Burkhart Pv, Rayens MK, Revelette WR, Ohlmann A, McCoy K, Shade
DM, et al. Improved health outcomes with peak flow monitoring for
children with asthma. J Asthma 2007;44(2):137-42.
836. McCoy K, Shade DM, Irvin CG, Mastronarde JG, Hanania NA, Castro
M, et al. Predicting episodes of poor asthma control in treated patients
with asthma. J Allergy Clin Immunol 2006;118(6):1226-33.
837. Nuijsink M, Hop WC, Sterk PJ, Duiverman EJ, de Jongste JC. Long-term
asthma treatment guided by airway hyperresponsiveness in children: a
randomised controlled trial. Eur Respir J 2007;30(3):457-66.
838. de Jongste JC, Carraro S, Hop WC, Group CS, Baraldi E. Daily
telemonitoring of exhaled nitric oxide and symptoms in the treatment
of childhood asthma. Am J Respir Crit Care Med 2009;179(2):93-7.
839. Fritsch M, Uxa S, Horak F, Putschoegl B, Dehlink E, Szepfalusi Z, et
al. Exhaled nitric oxide in the management of childhood asthma: a
prospective 6-months study. Pediatr Pulmonol 2006;41(9):855-62.
840. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric
oxide predicts asthma relapse in children with clinical asthma remission.
Thorax 2005;60(3):215-8.
841. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O’Connor GT,
Morgan WJ, et al. Management of asthma based on exhaled
nitric oxide in addition to guideline-based treatment for inner-city
adolescents and young adults: a randomised controlled trial. Lancet
2008;372(9643):1065-72.
142
842. Covar RA, Szefler SJ, Zeiger RS, Sorkness CA, Moss M, Mauger
DT, et al. Factors associated with asthma exacerbations during
a long-term clinical trial of controller medications in children.
J Allergy Clin Immunol 2008;122(4):741-7.
843. Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD. Forced
expiratory volume in 1 second percentage improves the
classification of severity among children with asthma. Pediatrics
2006;118(2):e347-55.
844. Zacharasiewicz A, Wilson N, Lex C, Erin EM, Li AM, Hansel
T, et al. Clinical use of noninvasive measurements of airway
inflammation in steroid reduction in children. Am J Respir Crit
Care Med 2005;171(10):1077-82.
845. Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma
Control Questionnaire in children: validation, measurement
properties, interpretation. Eur Respir J 2010;36(6):1410-6.
846. Bacharier LB, Guilbert TW, Zeiger RS, Strunk RC, Morgan WJ,
Lemanske Jr RF, et al. Patient characteristics associated with
improved outcomes with use of an inhaled corticosteroid in
preschool children at risk for asthma. J Allergy Clin Immunol
2009;123(5):1077-82.
847. Busse WW, Pedersen S, Pauwels RA, Tan WC, Chen yZ, Lamm
CJ, et al. The Inhaled Steroid Treatment As Regular Therapy in
Early Asthma (START) study 5-year follow-up: Effectiveness of
early intervention with budesonide in mild persistent asthma. J
Allergy Clin Immunol 2008;121(5):1167-74.
848. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled
corticosteroids in infants and preschoolers with recurrent
wheezing and asthma: a systematic review with meta-analysis.
Pediatrics 2009;123(3):e519-25.
849. Kerwin EM, Pearlman DS, de Guia T, Carlsson LG, Gillen M,
Uryniak T, et al. Evaluation of efficacy and safety of budesonide
delivered via two dry powder inhalers. Curr Med Res and Opin
2008;24(5):1497-510.
850. Knuffman JE, Sorkness CA, Lemanske RF, Jr., Mauger DT,
Boehmer SJ, Martinez FD, et al. Phenotypic predictors of
long-term response to inhaled corticosteroid and leukotriene
modifier therapies in pediatric asthma. J Allergy Clin Immunol
2009;123(2):411-6.
851. Kooi EMW, Schokker S, Marike Boezen H, de Vries TW,
vaessen-verberne AAPH, van der Molen T, et al. Fluticasone
or montelukast for preschool children with asthma-like
symptoms: randomized controlled trial. Pulm Pharmacol Ther
2008;21(5):798-804.
852. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA,
et al. Regular vs prn nebulized treatment in wheeze preschool
children. Allergy 2009;64(10):1463-71.
853. Rachelefsky G. Inhaled corticosteroids and asthma control
in children: assessing impairment and risk. Pediatrics
2009;123(1):353-66.
854. de Blic J, Ogorodova L, Klink R, Sidorenko I, valiulis A, Hofman
J, et al. Salmeterol/fluticasone propionate vs. double dose
fluticasone propionate on lung function and asthma control in
children. Pediatr Allergy Immunol 2009;20(8):763-71.
855. Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Strater C,
Steinkamp G, et al. Add-on salmeterol compared to double dose
fluticasone in pediatric asthma: A double-blind, randomized trial
(vIAPAED). Pediatr Pulmonol 2009;44(11):1132-42.
856. Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and
safety of a new pressurised metered-dose inhaler formulation
of budesonide/formoterol in children with asthma: a superiority
and therapeutic equivalence study. Pulm Pharmacol Ther
2008;21(1):152-9.
857. Pearlman D, Qaqundah P, Matz J, Yancey SW, Stempel DA,
Ortega HG. Fluticasone propionate/salmeterol and exerciseinduced
asthma in children with persistent asthma. Pediatr
Pulmonol 2009;44(5):429-35.
858. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T,
et al. Montelukast as add-on therapy to inhaled corticosteroids in
the treatment of mild to moderate asthma: a systematic review.
Thorax 2008;63(5):453-62.
859. Medicines and Healthcare products Regulatory Agency. 2010.
[cited 14 January]. Available from url: http://www.mhra.gov.uk/
Safetyinformation/DrugSafetyUpdate/CON093845
860. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, vidaurre
CF. Omalizumab for the treatment of exacerbations in children
with inadequately controlled allergic (IgE-mediated) asthma. J
Allergy Clin Immunol 2009;124(6):1210-6.
861. Raissy HH, Harkins M, Kelly F, Kelly HW. Pretreatment with
albuterol versus montelukast for exercise-induced bronchospasm
in children. Pharmacotherapy 2008;28(3):287-94.